Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Protagonist Therapeutics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by 3 distinct examiners within 1 art unit, creating examiner diversity within a consistent art-unit setting.
COFFA, SERGIO is the busiest examiner, with 1 pending matter. Counsel can use the common art-unit assignment to coordinate technical positions while tailoring responses to each examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
| MIKNIS, ZACHARY J | 1 | 68.5% | +32.4% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18355992 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | MIKNIS, ZACHARY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18492612 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | COFFA, SERGIO | — |
| 18355992 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | MIKNIS, ZACHARY J | — |
| 17792594 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1658 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18492612 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | COFFA, SERGIO | 1658 | §112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18355992 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | MIKNIS, ZACHARY J | 1658 | §101§112Other | Final Rejection | — | Pending | Jul 20, 2023 |
| 17792594 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | DABKOWSKI, ERINNE R | 1658 | §103§112DP | Non-Final OA | — | Pending | Jul 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProtagonist Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 1 art units and 3 examiners.
Sergio Coffa has the most, with 1 of Protagonist Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
